A sister-company of Oxford University is developing a new cancer treatment that can reprogram cancer cells to shrink tumours the university announced yesterday.
The company, called Argonaut and based at Oxford Science Park, is focusing on the treatments for colorectal cancer and lymphoma.
Researchers hopes to develop a ‘switch’ that directs cells to either grow and divide or die and activate ‘cell death mode’ which could in turn shrink potentially fatal tumours.
The company plans to undertake clinical trials at the Churchill Hospital.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here